Thomas Conlon, Chief Scientific Officer of Michelson Philanthropies, will speak on a panel about the future of the mRNA revolution during the Milken Institute’s Future of Health Summit.
Messenger RNA, or mRNA, has been a focus of research for scientists and drug developers for many years. It jumped to the forefront of the public consciousness when rapidly and successfully deployed as the platform for COVID-19 vaccines. The technology, however, promises to address a wider range of conditions, from cancers to cardiovascular disease to a broad array of infectious diseases. Learn more about the inner workings of mRNA and its promise as a treatment modality.
The Milken Institute’s Future of Health Summit convenes the best minds in the world to confront the most significant health challenges by matching human, financial, and scientific resources with the most innovative, inclusive, and impactful ideas.